Jim Cramer: Utilities Stocks 'Oversold,' Fastly 'Back From Abyss' - Cloudflare (NYSE:NET), Akamai Technol
Benzinga reports Jim Cramer’s comments alongside recent earnings updates. Vistra missed Q2 revenue and EPS estimates but grew adjusted EBITDA and reaffirmed full-year outlook. Recursion Pharmaceuticals reported worse-than-expected Q2 results. NextEra Energy had mixed Q2 results and reaffirmed guidance. Huntington Ingalls beat Q2 results and raised FY26 sales guidance. Fastly’s Q2 EPS beat estimates. Shares moved modestly.
How this was made
The 30-second read
Why it matters
It provides directional earnings outcomes (beat/miss, guidance reaffirmed/raised) and same-session stock moves, but lacks the underlying figures needed to quantify the market’s rationale.
Market read
Traders get a quick read on how markets reacted to recent earnings prints across several US names, but the article does not add new guidance numbers or filings.
What to watch
The article omits key earnings components (revenue vs consensus, guidance magnitude, segment performance, and balance-sheet/cash-flow details) that typically explain why stocks move opposite to headline EPS.
Background
The piece is a multi-company earnings snapshot with editorial commentary (Jim Cramer) and brief price-action bullets.
Ticker impact
Fastly reported quarterly earnings of 15 cents per share, beating consensus seven cents, and the stock fell 0.9% on the session.
Near-term downside bias or choppy trading until more detail (guidance, margins, bookings) is digested.
The article provides only EPS beat and same-day price move, with no guidance or segment detail to explain the disconnect.
NextEra Energy was flagged by Cramer as having “trouble” after mixed Q2 results, while reaffirming full-year adjusted EPS guidance.
Limited follow-through expected unless subsequent details (segment performance) disappoint.
The body states mixed results and guidance reaffirmation but does not provide the specific figures or what drove the “trouble” claim.
Huntington Ingalls reported better-than-expected Q2 results and raised FY26 sales guidance, yet shares fell 0.3% in the session.
Potential mean reversion higher if investors later focus on the raised FY26 sales guidance.
Only the guidance direction and same-day price move are provided; no magnitude or margin/cash-flow context is given.
Vistra gained 1.2% after reporting Q2 revenue and earnings that missed estimates, while stronger adjusted EBITDA growth and full-year outlook were reaffirmed.
Mild bullish bias if traders continue to weight adjusted EBITDA and reaffirmed outlook over GAAP earnings.
The article lacks the actual guidance numbers and does not explain the magnitude of the EBITDA beat versus expectations.
Recursion Pharmaceuticals reported worse-than-expected Q2 results and shares fell 1.8% to $3.29.
Bearish near-term bias, with volatility likely given the small share price and earnings miss.
The article links a worse-than-expected quarter to a same-day decline, providing a clear directional catalyst even without detailed figures.
Market effects
Utilities and industrials sentiment may remain choppy as earnings beats or guidance reaffirmations do not guarantee upside in the near term.
US-focused read-through only, with no cross-market policy or macro catalyst cited.
Limited, since the article centers on US-listed company earnings reactions.
Counterpoint
Price action may be driven by factors not mentioned (guidance details, margins, cash flow, or analyst revisions), so the headline EPS beat/miss may be an incomplete signal.
Key entities
- companyFastly
Reported Q2 EPS of 15 cents, beating consensus seven cents, while shares fell 0.9%.
- companyNextEra Energy
Reported mixed Q2 results and reaffirmed full-year adjusted EPS guidance, despite Cramer’s “trouble” framing.
- companyHuntington Ingalls Industries
Reported better-than-expected Q2 results and raised FY26 sales guidance, yet shares fell 0.3%.
- companyVistra
Reported Q2 revenue and earnings misses, but stronger adjusted EBITDA growth and reaffirmed full-year outlook; shares rose 1.2%.
- companyRecursion Pharmaceuticals
Reported worse-than-expected Q2 results; shares fell 1.8% to $3.29.
